Welcome to our dedicated page for MYL news (Ticker: MYL), a resource for investors and traders seeking the latest updates and insights on MYL stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect MYL's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of MYL's position in the market.
Mylan N.V. (NASDAQ: MYL) reported third quarter 2020 revenues of $2.97 billion, a slight year-on-year increase. North America net sales were $1.03 billion, down 5%, while Europe net sales rose 7% to $1.12 billion. U.S. GAAP net earnings totaled $185.7 million, showing a slight decline from $189.8 million last year. For the nine months ended September 30, total revenues reached $8.32 billion, with adjusted net earnings of $1.72 billion, up from $1.56 billion. Operating cash flow increased to $1.20 billion.
Mylan N.V. has appointed Bill Szablewski as the new Head of Capital Markets for Viatris, effective immediately. Szablewski brings nearly 15 years of experience in the healthcare sector, having previously worked at Bristol Myers Squibb. His role includes overseeing investor relations and treasury functions, while building Viatris' brand in global capital markets. This strategic move aims to strengthen relationships with equity and fixed income investors as the company prepares to launch as a new healthcare leader.
Mylan N.V. (NASDAQ: MYL) announced a significant ruling by the European Patent Office (EPO) that invalidates Teva's European Patent No. 2 949 335 for Copaxone® 40 mg/mL, allowing Mylan to expand market access in Europe. This decision results from over 11 years of litigation where Mylan successfully challenged Teva's patents. Mylan plans to accelerate the commercialization of its lower-cost, therapeutically equivalent version of Copaxone, benefiting many patients with multiple sclerosis across Europe.
Mylan N.V. (NASDAQ: MYL) announced that Executive Chairman Robert J. Coury and President Rajiv Malik will present at the Morgan Stanley Virtual 18th Annual Global Healthcare Conference on September 16, 2020, at 4:15 p.m. ET. They will be joined by Upjohn's President Michael Goettler and CFO Sanjeev Narula, who will lead Viatris. Interested parties can access the live webcast via Mylan's investor relations website. Mylan is committed to improving global healthcare with over 7,500 marketed products and operates in more than 165 countries, focusing on access to quality medicines.
Mylan N.V. (NASDAQ: MYL) will present at the BofA Securities Virtual Global Healthcare Conference on September 17, 2020, at 10:05 a.m. ET. Executive Chairman Robert J. Coury, President Rajiv Malik, Upjohn's Group President Michael Goettler, and CFO Sanjeev Narula will participate. Interested parties can access the live webcast on Mylan's investor relations website, with an archived version available later. Mylan, a global pharmaceutical leader, is committed to providing access to high-quality medicines and has a portfolio exceeding 7,500 products worldwide.
Mylan N.V. announced the acquisition of Aspen Pharmacare Holdings Limited's thrombosis business in Europe for EUR 641.9 million, expected to close by December 31, 2020. The deal includes an upfront payment of EUR 263.2 million and deferred payment of EUR 378.7 million by June 25, 2021. The acquired portfolio, which includes established injectable anticoagulants, generated EUR 231 million in net sales in the past year. This acquisition is anticipated to enhance Mylan's market position and EBITDA margins, establishing it as the second largest supplier in Europe for these products.
Mylan N.V. (NASDAQ: MYL) and Biocon Biologics India Ltd. announced the U.S. launch of Semglee™ (insulin glargine injection) to assist patients with type 1 and type 2 diabetes. Approved by the FDA, Semglee has an identical amino acid sequence to Sanofi's Lantus® and is priced competitively at $147.98 for five 3ml pens and $98.65 for a 10ml vial, the lowest among long-acting insulins. The collaboration aims to increase availability and affordability of diabetes treatment in the U.S., with an ambition to reach 5 million patients by FY22 and achieve $1 billion in revenue.
Mylan N.V. (NASDAQ: MYL) has announced a voluntary nationwide recall of four lots of Amiodarone HCl Injection and Tranexamic Acid Injection due to critical carton labeling errors. These products, distributed to wholesalers and hospital pharmacies, could contain mislabeled vials, posing severe risks to patient safety. Both medications are only to be used by trained healthcare professionals. Mylan has reported no adverse events linked to this recall to date. The company is notifying distributors and arranging product returns.
Mylan N.V. has launched the first FDA-approved generic version of Biogen's Tecfidera, marking a significant milestone in MS treatment options. This product, available in 120 mg and 240 mg delayed-release capsules, offers a more affordable alternative for patients. The FDA's approval followed Mylan's legal victory that invalidated Biogen's patent for Tecfidera, which generated about $3.79 billion in U.S. sales over the past year. Mylan aims to enhance access to medicines while continuing to support the MS community.
Mylan N.V. (NASDAQ: MYL) has announced a $1 million donation to Sesame Workshop to develop educational resources aimed at aiding children and families affected by the COVID-19 pandemic. These resources will address socio-emotional challenges such as anxiety and grief and will be available in multiple languages as part of Sesame's 'Caring for Each Other' initiative. Mylan aims to support its 35,000 employees and their families by sharing these materials widely, ensuring access to critical socio-emotional support globally.
